GlassScriptPhysician profile
Julia A Vasta
NPI 1487645883
$9,901.69
in general payments reported to CMS, 2019-2025
38 companies · $2,056 in 2025
The $2,056 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,039 · 2022: $2,368 · 2023: $1,834 · 2024: $1,604 · 2025: $2,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,494.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,223.67 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $944.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $919.13 | 2021-2025 | |
| Abbvie INC. | $813.25 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $771.16 | 2021-2025 | |
| Amgen INC. | $762.97 | 2021-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $690.01 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.66 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $280.60 | 2021-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $277.98 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $276.32 | 2025 | Zoryve |
| Exact Sciences Corporation | $226.68 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.44 | 2025 | Caplyta |
| Abbott Laboratories | $207.05 | 2021-2025 | Freestyle Libre 2 |
| Astellas Pharma US INC | $205.52 | 2021-2023 | Myrbetriq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $202.86 | 2021-2024 | |
| Dexcom, INC. | $192.94 | 2022-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $179.64 | 2021-2022 | |
| Amarin Pharma, INC. | $154.64 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.31 | 2022-2024 | Farxiga, Evusheld, Airsupra |
| Corcept Therapeutics | $108.50 | 2022-2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.00 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $93.88 | 2025 | Voquezna |
| Corium, LLC | $91.03 | 2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $88.22 | 2022 | |
| Sumitomo Pharma America, INC. | $85.66 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $47.47 | 2021 | |
| Radius Health, INC. | $37.49 | 2023 | Tymlos |
| Nevro Corp. | $34.55 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $34.33 | 2023 | Quviviq |
| Scpharmaceuticals INC. | $27.02 | 2025 | |
| Neurocrine Biosciences, INC. | $26.97 | 2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $26.54 | 2021 | |
| Antares Pharma, INC. | $19.51 | 2022 | |
| Lundbeck LLC | $16.48 | 2023 | Rexulti |
| Bioventus LLC | $13.90 | 2023 | Exogen Ultrasound Bone Healing System |
| Currax Pharmaceuticals LLC | $13.82 | 2025 | Onzetra Xsail, Contrave |
| Arbor Pharmaceuticals, INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Vasta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.